Latest Financial Growth News

Oceania Healthcare reported a 4.1% rise in underlying EBITDA for FY25, driven by strong sales and operational improvements, while launching a new strategic plan focused on growth and efficiency.

Bell Financial Group delivered strong financial results for 2024, driven by growth in technology and product services, but early 2025 shows challenges from market volatility impacting core broking revenues.

Technology One Limited has reported a record half-year performance, with revenue up 19% and net profit after tax rising 31%, driven by strong SaaS growth and strategic acquisitions.

Smartgroup Corporation Limited reported robust financial growth in 2024, driven by record customer numbers and a significant rise in electric vehicle leasing, positioning the company for a sustainable future.

Aeeris Ltd delivered solid Q3 FY2025 results, driven by strong recurring revenue growth, a successful new product launch, and strategic moves to internalise key forecasting capabilities.

Smart Parking Limited has reported a robust half-year performance with a 20% increase in revenue and a 70% rise in net profit, driven by international expansion and operational growth across multiple markets.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Pro Medicus Limited has reported a robust half-year financial performance for the period ending December 31, 2024, with net profit soaring 42.7% and an increased interim dividend declared.

IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.